These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 1438243)

  • 21. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.
    Mirsaliotis A; Lamb D; Brighty DW
    J Virol; 2008 May; 82(10):4965-73. PubMed ID: 18305034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region.
    N A PI; Li GM; Warachit J; Iwabu Y; Tsuji S; Auwanit W; Yamamoto D; Goto T; Hayashi Y; Kiso Y; Ikuta K
    Microbes Infect; 2005 Mar; 7(3):356-64. PubMed ID: 15780966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A synthetic peptide "T22" as anti-HIV agents].
    Nakashima H; Murakami T
    Nihon Rinsho; 1993 Sep; 51 Suppl():146-52. PubMed ID: 8271378
    [No Abstract]   [Full Text] [Related]  

  • 25. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
    Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence.
    Barbouche R; Sabatier JM; Fenouillet E
    Virology; 1998 Aug; 247(2):137-43. PubMed ID: 9705906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
    Fenouillet E; Miquelis R; Drillien R
    Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Düzgünes N
    Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
    Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
    Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin.
    Gordon LM; Curtain CC; McCloyn V; Kirkpatrick A; Mobley PW; Waring AJ
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1145-56. PubMed ID: 8312056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Campbell AP; Sykes BD; Norrby E; Assa-Munt N; Dyson HJ
    Fold Des; 1996; 1(2):157-65. PubMed ID: 9079375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution.
    Klasse J; Pipkorn R; Blomberg J; Han KH; Hilton B; Ferretti JA
    FEBS Lett; 1993 May; 323(1-2):68-72. PubMed ID: 8495750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.
    Giannecchini S; Di Fenza A; D'Ursi AM; Matteucci D; Rovero P; Bendinelli M
    J Virol; 2003 Mar; 77(6):3724-33. PubMed ID: 12610147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extensive C-terminal deletion in human immunodeficiency virus type 1 Env glycoprotein arising after long-term culture of chronically infected cells.
    Zaides V; Yagello M; Veselovskaya T; Schmitt D; Rykova L; Fenouillet E; Gluckman JC
    J Gen Virol; 1994 Nov; 75 ( Pt 11)():2963-75. PubMed ID: 7964606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.
    Lambert DM; Barney S; Lambert AL; Guthrie K; Medinas R; Davis DE; Bucy T; Erickson J; Merutka G; Petteway SR
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):2186-91. PubMed ID: 8700906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
    Hallenberger S; Bosch V; Angliker H; Shaw E; Klenk HD; Garten W
    Nature; 1992 Nov; 360(6402):358-61. PubMed ID: 1360148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.